<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">41913</article-id><article-id pub-id-type="doi">10.7554/eLife.41913</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title><italic>GREB1</italic> amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-122489"><name><surname>Lee</surname><given-names>Eugine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-86467"><name><surname>Wongvipat</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-122490"><name><surname>Choi</surname><given-names>Danielle</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-40377"><name><surname>Wang</surname><given-names>Ping</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-127642"><name><surname>Lee</surname><given-names>Young Sun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-40378"><name><surname>Zheng</surname><given-names>Deyou</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4354-5337</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-3586"><name><surname>Watson</surname><given-names>Philip A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-122491"><name><surname>Gopalan</surname><given-names>Anuradha</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-1025"><name><surname>Sawyers</surname><given-names>Charles L</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4955-6475</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="other" rid="par-9"/><xref ref-type="other" rid="par-10"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><institution content-type="dept">Human Oncology and Pathogenesis Program</institution>, <institution>Memorial Sloan Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Genetics</institution>, <institution>Albert Einstein College of Medicine</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Pathology</institution>, <institution>Memorial Sloan Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-99932"><name><surname>Tannock</surname><given-names>Ian</given-names></name><role>Reviewing editor</role><aff><institution>Princess Margaret Cancer Centre</institution>, <country>Canada</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>sawyersc@mskcc.org</email> (CS);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>15</day><month>01</month><year>2019</year></pub-date><volume>8</volume><elocation-id>e41913</elocation-id><history><date date-type="received"><day>11</day><month>09</month><year>2018</year></date><date date-type="accepted"><day>27</day><month>12</month><year>2018</year></date></history><permissions><copyright-statement>Â© 2019, Lee et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Lee et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-41913-v1.pdf"/><abstract><p>Genomic amplification of the androgen receptor (<italic>AR</italic>) is an established mechanism of antiandrogen resistance in prostate cancer. Here we show that the magnitude of <italic>AR</italic> signaling output, independent of <italic>AR</italic> genomic alteration or expression level, also contributes to antiandrogen resistance, through upregulation of the coactivator <italic>GREB1</italic>. We demonstrate 100-fold heterogeneity in <italic>AR</italic> output within human prostate cancer cell lines and show that cells with high <italic>AR</italic> output have reduced sensitivity to enzalutamide. Through transcriptomic and shRNA knockdown studies, together with analysis of clinical datasets, we identify <italic>GREB1</italic> as a gene responsible for high <italic>AR</italic> output. We show that <italic>GREB1</italic> is an <italic>AR</italic> target gene that amplifies <italic>AR</italic> output by enhancing <italic>AR </italic>DNA binding and promoting <italic>EP300</italic> recruitment. <italic>GREB1</italic> knockdown in high <italic>AR</italic> output cells restores enzalutamide sensitivity in vivo. Thus, <italic>GREB1</italic> is a candidate driver of enzalutamide resistance through a novel feed forward mechanism.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA008748</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA155169</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id><institution>U.S. Department of Defense</institution></institution-wrap></funding-source><award-id>W81XWH-15-1-0540</award-id><principal-award-recipient><name><surname>Lee</surname><given-names>Eugine</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>Starr Cancer Consortium</institution></institution-wrap></funding-source><award-id>I10-0062</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>Iris &amp; Junming Le Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lee</surname><given-names>Eugine</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA193837</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA224079</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA092629</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><award-group id="par-10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA160001</award-id><principal-award-recipient><name><surname>Sawyers</surname><given-names>Charles L</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>John Wongvipat, co-inventor of enzalutamide.</p></fn><fn fn-type="conflict" id="conf3"><p>Charles L Sawyers, Senior editor, <italic>eLife</italic>; Board of Directors of Novartis; co-founder of ORIC Pharm; co-inventor of enzalutamide and apalutamide; Science advisor to Agios, Beigene, Blueprint, Column Group, Foghorn, Housey Pharma, Nextech, KSQ, Petra and PMV; co-founder of Seragon, purchased by Genentech/Roche in 2014.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal experiments were performed in compliance with the approved institutional animal care and use committee (IACUC) protocols (#06-07-012) of the Research Animal Resource Center of Memorial Sloan Kettering Cancer Center.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>RNA-seq data has been deposited in GEO under accession code GSE120720.  ChIP-seq data has been deposited in GEO under accession code GSE120680</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Lee E</collab><collab>Wongvipat J</collab><collab>Choi D</collab><collab>Wang P</collab><collab>Lee YS</collab><collab>Zheng D</collab><collab>Watson PA</collab><collab>Gopalan A</collab><collab>Sawyers CL</collab></person-group><year iso-8601-date="2018">2018</year><source>GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120720">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120720</ext-link><comment>NCBI Gene Expression Omnibus, GSE120720</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Lee E</collab><collab>Wongvipat J</collab><collab>Choi D</collab><collab>Wang P</collab><collab>Lee YS</collab><collab>Zheng D</collab><collab>Watson PA</collab><collab>Gopalan A</collab><collab>Sawyers CL</collab></person-group><year iso-8601-date="2018">2018</year><source>GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120680">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120680</ext-link><comment>NCBI Gene Expression Omnibus, GSE120680</comment></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Robinson D et al</collab></person-group><year iso-8601-date="2015">2015</year><source>Integrative clinical genomics of advanced prostate cancer</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/gap/?term=phs000915.v1.p1">https://www.ncbi.nlm.nih.gov/gap/?term=phs000915.v1.p1</ext-link><comment>NCBI dbGap, phs000915.v1.p1</comment></element-citation><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2015">2015</year><source>The Molecular Taxonomy of Primary Prostate Cancer</source><ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org/study.do?cancer_study_id=prad_tcga_pub">http://www.cbioportal.org/study.do?cancer_study_id=prad_tcga_pub</ext-link><comment>cBioPortal for Cancer Genomics</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-41913-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>